The debate about the adoption of green technologies (GTs) is trending due to increasing environmental concerns across the globe. In the context of the manufacturing industry, the research about enablers to GT adoption while using the ISM-MICMAC approach is scarce. Hence, the empirical analysis of GT enablers is being done in this study using a novel ISM-MICMAC method. Firstly, the research framework is developed by using the ISM-MICMAC methodology. Then, enablers to GTs were extracted from existing studies and validated by experts. Results showed that the most significant enabler to GT adoption is providing incentives for green manufacturers (1) in the ISM model. So, manufacturing firms must take initiatives for GTs to mitigate the negative environmental impact of industrialization without losing their earnings. This research brings substantial empirical scholarship to understand GT enablers and their contribution in GT enabler incorporation in the manufacturing industry of developing economies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11356-023-25744-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Australian automotive workers and community leaders interview dataset following 2017 assembly plant closures.
Sci Data
January 2025
UniSA Business, University of South Australia, Adelaide, Australia.
The Australian manufacturing sector saw the exit of the automotive industry in 2017 arising in mass retrenchment across its assembly plants and supply chain firms. In 2019, a large-scale program of research was launched to investigate the impacts of the closures on workers and community including a dedicated stream of qualitative work which took place in 2021. This work took the form of in-depth interviews that investigated the experiences of automotive workers as they underwent retrenchment, reskilling, re-employment and retirement.
View Article and Find Full Text PDFNext-generation vaccines for influenza B virus: advancements and challenges.
Arch Virol
January 2025
CAS Key Laboratory of Molecular Virology & Immunology, Institutional Center for Shared Technologies and Facilities, Pathogen Discovery and Big Data Platform, Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, Yueyang Road 320, Shanghai, 200031, China.
To battle seasonal outbreaks of influenza B virus infection, which continue to pose a major threat to world health, new and improved vaccines are urgently needed. In this article, we discuss the current state of next-generation influenza B vaccine development, including both advancements and challenges. This review covers the shortcomings of existing influenza vaccines and stresses the need for more-effective and broadly protective vaccines and more-easily scalable manufacturing processes.
View Article and Find Full Text PDFAccelerating biosimilar market access: the case for allowing earlier standing.
J Law Biosci
January 2025
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, 1620 Tremont St. Suite 3030, Boston, MA 02120, USA.
Biosimilars, which are affordable alternatives to biologic medicines, face delays in market entry due to the current patent litigation framework under the Biologic Price Competition and Innovation Act. Currently, biosimilar manufacturers can only initiate patent litigation to attempt to clear weak and invalid patents after submitting their Biologic License Application to the Food and Drug Administration (FDA), which happens after completing extensive, and costly clinical trials. By contrast, generic drug manufacturers can start litigation earlier due to shorter development times and less stringent clinical requirements, allowing them to launch immediately after the primary patent expires.
View Article and Find Full Text PDFThe impact of the centralized volume-based procurement policy on Chinese pharmaceutical manufacturing firms' R&D investment: A difference-in-differences approach.
PLoS One
January 2025
School of Economics and Management, Tongji University, Shanghai, China.
Article Synopsis
- Centralized drug procurement, like China's 2018 CVBP, aims to ease healthcare costs and enhance the pharmaceutical industry.
- Research on the impact of this procurement method shows it significantly boosts R&D investment among pharmaceutical firms, especially those with high marketing expenses.
- The study utilizes data from listed firms in China's A-share market, confirming the findings through various robust testing methods, thus offering valuable insights for governments and firms on fostering innovation.
Green credit policy and energy consumption intensity in China: Firm-level evidence and insights.
J Environ Manage
January 2025
College of Business and Public Management, Department of Economics, Wenzhou-Kean University, Wenzhou, China; Centre for Studies on Europe, Azerbaijan State University of Economics, Baku, Azerbaijan; Division of International Studies, College of International Studies, Korea University. 145 Anam-ro, Seongbuk-gu, Seoul, 02841, Republic of Korea. Electronic address:
The transition to sustainable development has become a global priority, with energy transformation serving as a key component. In this context, green financial instruments play a crucial role in shaping corporate energy-saving behaviors and promoting sustainable development. This paper examines the impact and mechanism of China's first green credit policy (GCP) on energy consumption intensity (ECI) of manufacturing firms in China, using a difference-in-difference (DID) approach with micro-level data (2004-2009).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!